Show simple item record

FieldValueLanguage
dc.contributor.authorBull, Rowenaen_AU
dc.contributor.authorAbayasingam, Arunasingamen_AU
dc.contributor.authorBalachandran, Harikrishnanen_AU
dc.contributor.authorAgapiou, Daviden_AU
dc.contributor.authorRodrigo, Chaturakaen_AU
dc.contributor.authorKeoshkerian, Elizabethen_AU
dc.contributor.authorLi, Huien_AU
dc.contributor.authorBrasher, Nicholasen_AU
dc.contributor.authorChrist, Danielen_AU
dc.contributor.authorRouet, Romainen_AU
dc.contributor.authorBurnett, Deborahen_AU
dc.contributor.authorGrubor-Bauk, Brankaen_AU
dc.contributor.authorRawlinson, Williamen_AU
dc.contributor.authorTurville, Stuarten_AU
dc.contributor.authorAggarwal, Anupriyaen_AU
dc.contributor.authorBrilot, Fabienneen_AU
dc.contributor.authorMina, Michaelen_AU
dc.contributor.authorPost, Jeffreyen_AU
dc.contributor.authorHudson, Bernarden_AU
dc.contributor.authorGilroy, Nickyen_AU
dc.contributor.authorDwyer, Dominicen_AU
dc.contributor.authorSasson, Sarahen_AU
dc.contributor.authorTea, Fionaen_AU
dc.contributor.authorPilli, Deeptien_AU
dc.contributor.authorTedla, Nicodemusen_AU
dc.contributor.authorLloyd, Andrewen_AU
dc.contributor.authorMartinello, Marianneen_AU
dc.date.accessioned2020-12-21
dc.date.available2020-12-21
dc.date.issued2020en_AU
dc.identifier.urihttps://hdl.handle.net/2123/24220
dc.description.abstractConsiderable concerns relating to the duration of protective immunity against SARS-CoV-2 have been raised, with evidence of antibody titres declining rapidly after infection and reports of reinfection. Here we monitored antibody responses against SARS-CoV-2 receptor binding domain (RBD) for up to six months after infection. While antibody titres were maintained, half of the cohort's neutralising responses had returned to background. However, encouragingly in a selected subset of 13 participants, 12 had detectable RBD-specific memory B cells and these generally increased out to 6 months. Furthermore, we were able to generate monoclonal antibodies with SARS-CoV-2 neutralising capacity from these memory B cells. Overall our study suggests that the loss of neutralising antibodies in plasma may be countered by the maintenance of neutralising capacity in the memory B cell repertoire.en_AU
dc.language.isoenen_AU
dc.subjectCOVID-19en_AU
dc.subjectCoronavirusen_AU
dc.titleLong-term persistence of neutralizing memory B cells in SARS-CoV-2en_AU
dc.typePreprinten_AU
dc.identifier.doi10.21203/rs.3.rs-92527/v1


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.